Humana Inc. $HUM Shares Acquired by J. Safra Sarasin Holding AG

J. Safra Sarasin Holding AG increased its position in shares of Humana Inc. (NYSE:HUM) by 248.0% in the 3rd quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 4,332 shares of the insurance provider’s stock after purchasing an additional 3,087 shares during the period. J. Safra Sarasin Holding AG’s holdings in Humana were worth $1,127,000 as of its most recent SEC filing.

Other hedge funds have also recently added to or reduced their stakes in the company. Massachusetts Financial Services Co. MA increased its position in Humana by 273.2% during the 3rd quarter. Massachusetts Financial Services Co. MA now owns 3,488,261 shares of the insurance provider’s stock worth $907,541,000 after purchasing an additional 2,553,509 shares during the period. Norges Bank purchased a new stake in shares of Humana in the second quarter valued at approximately $397,079,000. Leith Wheeler Investment Counsel Ltd. boosted its stake in shares of Humana by 661.7% in the second quarter. Leith Wheeler Investment Counsel Ltd. now owns 1,038,703 shares of the insurance provider’s stock valued at $253,942,000 after buying an additional 902,340 shares in the last quarter. Dodge & Cox grew its holdings in Humana by 5.6% during the second quarter. Dodge & Cox now owns 11,352,920 shares of the insurance provider’s stock worth $2,775,562,000 after acquiring an additional 597,705 shares during the period. Finally, 8 Knots Management LLC raised its position in Humana by 671.0% in the second quarter. 8 Knots Management LLC now owns 441,623 shares of the insurance provider’s stock worth $107,968,000 after acquiring an additional 384,345 shares in the last quarter. Institutional investors and hedge funds own 92.38% of the company’s stock.

Wall Street Analysts Forecast Growth

HUM has been the topic of several research analyst reports. Truist Financial decreased their target price on shares of Humana from $300.00 to $285.00 and set a “hold” rating on the stock in a research report on Monday, November 10th. Bank of America raised their price objective on shares of Humana from $280.00 to $300.00 and gave the company a “neutral” rating in a research note on Friday, October 10th. Weiss Ratings reissued a “sell (d+)” rating on shares of Humana in a report on Thursday, January 22nd. KeyCorp restated a “sector weight” rating on shares of Humana in a research report on Friday, December 12th. Finally, Barclays reiterated an “underperformer” rating on shares of Humana in a research report on Monday, January 5th. Eight analysts have rated the stock with a Buy rating, nine have issued a Hold rating and five have assigned a Sell rating to the company’s stock. According to data from MarketBeat, Humana presently has an average rating of “Hold” and an average price target of $293.37.

Trending Headlines about Humana

Here are the key news stories impacting Humana this week:

• Positive Sentiment: Some market commentators frame the selloff as a buying opportunity given Humana’s scale in Medicare Advantage and recent outperformance vs. peers; this view argues the weakness may create a value entry point. Humana’s Health Scare Sinks Stock To 9-Year Low. Time To Buy?
• Neutral Sentiment: Upcoming catalyst: Humana will present fourth‑quarter and full‑year 2025 results on Feb. 6 — this report and guidance will be a key near‑term test of whether the company can offset payment pressure with expense control or membership gains. Humana to Present Fourth-Quarter and Full-Year 2025 Results on 6 February
• Neutral Sentiment: Valuation debate: commentators are split between calling HUM a discounted value play vs. a potential value trap if Medicare rate pressure persists — expect divergent analyst takes in the coming days. Is Humana Stock Now A Value Trap At $200?
• Negative Sentiment: Primary driver of the selloff: the CMS proposal to keep Medicare Advantage rates roughly flat for 2027 reduces expected revenue growth for carriers and increases uncertainty about 2026–27 margins; UnitedHealth led the rout and Humana was hit hard as a large MA operator. UnitedHealth Leads $80 Billion Insurer Rout on Bleak Medicare Advantage Proposal
• Negative Sentiment: Market reaction: Humana plunged ~21% on the Medicare payment update, hitting multi‑year lows and signaling accelerated downside risk as investors reprice MA exposure. Humana (HUM) Falls 21% on Medicare Payment Update
• Negative Sentiment: Analyst commentary: several outlets and analysts warn there’s “no quick fix” for the rate shock — if CMS finalizes low increases, Humana may face sustained margin pressure and slower earnings growth. UnitedHealth, Humana: CMS’ Rate Decision Has Crushed Stock, & There’s No Quick Fix
• Negative Sentiment: Structural/operational risks: reporting suggests tighter CMS rates could collide with expanding at‑home cardiac care and other cost-heavy initiatives, and there are localized provider/contract risks (e.g., potential partner terminations) that could further pressure membership or margins. Humana Faces Tight CMS Rates As At Home Cardiac Care Expands Queen’s May Cut Ties With This For-Profit Medicare Insurer

Humana Price Performance

Shares of NYSE HUM opened at $193.89 on Thursday. The company has a current ratio of 2.02, a quick ratio of 2.02 and a debt-to-equity ratio of 0.68. The company’s 50-day moving average price is $257.61 and its 200 day moving average price is $264.43. Humana Inc. has a 52 week low of $191.39 and a 52 week high of $315.35. The stock has a market cap of $23.32 billion, a price-to-earnings ratio of 18.17, a PEG ratio of 1.71 and a beta of 0.45.

Humana (NYSE:HUM) last announced its quarterly earnings results on Wednesday, November 5th. The insurance provider reported $3.24 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.95 by $0.29. The company had revenue of $32.65 billion for the quarter, compared to the consensus estimate of $31.99 billion. Humana had a net margin of 1.02% and a return on equity of 12.86%. The company’s revenue for the quarter was up 11.1% compared to the same quarter last year. During the same quarter in the prior year, the firm earned $4.16 earnings per share. As a group, research analysts forecast that Humana Inc. will post 16.47 earnings per share for the current fiscal year.

Humana Company Profile

Humana Inc (NYSE: HUM) is a health insurance company headquartered in Louisville, Kentucky, that primarily serves individuals and groups across the United States. The company is best known for its Medicare business, offering Medicare Advantage plans and prescription drug (Part D) coverage, alongside a range of commercial and employer-sponsored group health plans. Humana’s products are designed to cover medical, behavioral health and pharmacy needs for members, with particular emphasis on seniors and Medicare-eligible populations.

In addition to traditional insurance products, Humana provides care-management and wellness services intended to support chronic-condition management, preventive care and care coordination.